How Much Weight Can You Lose on Semaglutide — and What Shapes That Number?

One transparent price covering your free consultation, prescription, treatment, and free next-working-day tracked delivery, nothing added at checkout.
Every consultation is personally reviewed the same day by a GPhC-registered Independent Prescriber, not software.
No subscription, no auto-renewal, every repeat order is clinically re-reviewed before dispatch.
Priority aftercare seven days a week, so you have clinical support at every stage of treatment.

In clinical trials, adults taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks alongside a reduced-calorie diet and increased activity — roughly 15–16 kg for someone starting at 100 kg. How much you lose on semaglutide in practice depends on your starting weight, how long you stay on treatment, and whether lifestyle changes run alongside it. Semaglutide (sold as Wegovy for weight management) is a prescription-only medicine; a qualified prescriber assesses whether it is clinically suitable before any treatment begins. That clinical step is not optional, and it matters for results as much as it does for safety.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the trial results actually mean for your costs, and why the price you pay should follow the care you get

The myth worth clearing up: a bigger number on the box doesn't mean a bigger number on the scale

A lot of people arrive at the question of semaglutide results having already decided that the highest dose must produce the best outcome for them personally. That's understandable, and it's also where the thinking can go sideways. Trial averages are exactly that, averages drawn from thousands of participants. The STEP 1 trial, published in the New England Journal of Medicine, reported roughly 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose, alongside diet and activity changes. Some participants lost considerably more; others less. Genetics, baseline weight, how consistently treatment runs, and what happens alongside the pen all feed into where any individual lands. A prescriber who knows your full picture is far better placed to set realistic expectations than a headline percentage. That doesn't mean the data is unimpressive, 15% average over 68 weeks, in a well-controlled trial, is a substantial clinical result. It just means the number is a range, not a promise, and it's worth holding it that way.

How much can you lose on semaglutide in a month, and what drives month-to-month variation?

Early in treatment, when doses are low for tolerability reasons, weight change tends to be modest. The titration schedule works up gradually, and the months on the maintenance dose tend to show the greatest effect. So asking how much you lose on semaglutide in a month produces a different answer depending on which month you mean. Across the full 68-week STEP 1 period, the average monthly rate of loss was roughly 0.9–1.0 kg, but that flattens out a ramp that starts gently and steepens as the dose increases. People who stay on treatment longer, maintain the lifestyle changes their prescriber recommended, and keep their clinical support in place tend to do better. Those who stop early because of side effects, or who treat the injection as a standalone fix, tend to see results tail off. The clinical support element is not a soft add-on. It's part of the mechanism.

For a fuller breakdown of what individual factors affect total loss when taking semaglutide, this page explores the variables in more detail.

What private semaglutide costs in the UK, and what the headline price often leaves out

UK private treatment prices for semaglutide vary between providers and by dose. Since Novo Nordisk's pricing moves and broader market changes through 2025, typical private prices have ranged from roughly £149 to over £300 per month depending on dose and provider, these figures are widely reported and should be treated as indicative rather than fixed. A detailed breakdown of Wegovy pricing in the UK covers how those ranges work in practice.

What headline prices often omit: some providers charge separately for the initial consultation, the prescription itself, and delivery. Aftercare (the ongoing clinical support that actually influences your results) is sometimes absent entirely, or gated behind an additional fee. That matters because semaglutide is not a medicine you titrate and manage without clinical input; it's a prescription-only treatment requiring regular review. When comparing costs, the fair comparison is total cost of a supervised month, not the lowest listed pen price. See how to read a semaglutide quote honestly before committing to any provider.

Why the cheapest route is often the most expensive one

For a prescription medicine, price is the wrong test. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online and via social media, fake pens seized in the UK have contained insulin instead of semaglutide, and enforcement operations through 2025 removed around 20 million doses of illegally traded weight-loss medicines worth approximately £45m from the supply chain. A low price from an unverified seller is a red flag, not a bargain. You can verify any online pharmacy on the GPhC register, it takes thirty seconds and tells you immediately whether a pharmacy is regulated.

At nume, we are not the cheapest option. That's a deliberate choice. One price covers consultation, prescription, treatment, and free next-working-day DPD delivery in plain packaging. There are no hidden fees. You can explore what's included on our treatment page, and our about us page explains the clinical infrastructure behind the service. If you have questions before starting, our FAQs cover the most common ones, and our team is available seven days a week.

A small saving on a pen that arrives from an unverified source, with no prescriber review and no aftercare, answers the wrong question entirely. The right question is whether the care behind the medicine is good enough to produce the results you're looking for. Check your eligibility and start your free consultation with a prescriber who can give you a straight answer about what to expect.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions